Selective 5-HT2C agonists as potential antidepressants

IDrugs

Volumn 2, Issue 2, 1999, Pages 109-120

  Leysen, Dirk C M ^a  

^a Scientif O Development Group   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; PAROXETINE; TRAZODONE; VENLAFAXINE;

AGGRESSION; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERANCE; EATING DISORDER; OBSESSION; PANIC; RELAPSE; REVIEW;

EID: 0033061586     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (148)

1. Angst J, Hochstrasser B. Recurrent brief depression. the Zurich study. J Clin Psychiatry (1994) 55 (Suppl).3-9.
2. Finder RM, Wieringa JH. Third-generation antidepressants. Med Res Rev (1993) 13.259-325.
3. Leonard BE, Spencer PSJ (Eds). Antidepressants. thirty years on. Clinical Neuroscience, London, (1990).
4. Broekkamp CLE, Leysen D, Peelers BWMM, Rinder RM. Prospects for improved antidepressants. J Med Chem (1995)38.4615-4630.
5. Pinder RM. Why more antidepressants? Pharm News (1996)3.11-14.
6. Henry JA. A fatal toxicity index for antidepressant poisoning. Acta Psychiat Scant/ (1989) 354.37-45.
7. Bourin M, Baker GB. The future of antidepressants. Biomed & PharmacotherC\99G) 50.7-12.
8. Efthymiou ML, Castot A. Antidepressants and cardiac side effects, tentative of prediction. Therapie (1992) 47.375-381.
9. Blier P, de MontignyC, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments. preclinical evidence. J Clin Psychiatry (1990) 51(Suppl4).14-20.
10. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sd (1994) 15.220226.
11. Gaddumand JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmacol (I957) 12.323-328.
12. Julius D, MacDermott AB, Axel R, Jessell TM. Molecular characterization of a functional cDNA encoding the serotonin 1 c receptor. Science (1988) 241.558-564.
13. Hoyer D, Martin GR. Classification and nomenclature of 5-HT receptors. a comment on current issues. Behav Brain Res (1996)73.263-268.
14. Hoyer D, Martin GR. 5-HT receptor classification and nomenclature. towards a harmonization with the human genome. Neuropharmacology (1997) 36.419-428.
15. Quick MW, Simon Ml, Davidson N, Lester HA, Aragay AM. Differential coupling of G protein alpha subunits to sevenhelix receptors expressed in Xenopus oocytes. J Bio! Chem (1994) 269.30164-30172.
16. Pandey SC, Davis JM, Pandey GN. Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates. J Psychiatry Neurosci (1995) 20.215-225.
17. Julius D, Huang KN, Livelli TJ, Axel R, Jessell TM. The 5-HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors. Proc Natl AcadSci USA (1990) 87.928-932.
18. Zifa E, Pillion G. 5-Hydroxytryptamine receptors. Pharmacol Rev (1992) 44.401 -458.
19. Boess FG, Martin IL. Molecular biology of 5-HT receptors. Neuropharmacol (1994) 33.275-317.
20. Stam NJ, Vanderheyden P, van Alebeek C, Klomp J, de Boer T, van Delft AML, Olijve W. Genomic organisation and functional expression of the gene encoding the human serotonin 5-HT2C receptor. Eur J Pharmacol (1994) 269.339-348.
21. Lucas JJ, Hen R. New players in the 5-HT receptor field. genes and knockouts. Trends Pharmacol Sci(1995) 16.246252.
22. Pandey SC, Davis JM, Pandey GN. Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates. J Psychiat Neurosci (1995) 20.215-225.
23. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature (1995) 374.542-546.
24. Chamey DS, Heninger GR, Reinhard JF, Stemberg DE, Hofstead KM. The effect of intravenous L-tryptophan on prolactin and growth hormone and mood in healthy subjects. Psychopharm (1982) 77.217-222.
25. Van Praag HM. Serotonin precursors in the treatment of depression. In. Serotonin in biological psychiatry. Ho BT, Schoolar JC, Usdin E (Eds), Raven Press, New York (1982).259-286.
26. Ward NG, Ang J, Pavinich G. A comparison of the acute effects of dextro-amphetamine and fenfluramine in depression. Biol Psychiatry (1985) 20.1090-1097.
27. Mueller EA, Murphy DL, Sunderland T. Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist in humans. J Clin Endocrinol Metab (1985) 61.1179-1184.
28. Mueller EA, Murphy DL, Sunderland T. Further studies of the putative serotonin agonist, mchlorophenylpiperazine. evidence for a serotonin receptor mediated mechanism of action in humans. PsychoptiarmiKo! (198C) 89.388-391.
29. Quested DJ, Sargent PA, Cowen PJ. SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology(\997) 133.305-308.
30. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL Serotonergic responsivity In obsessive-compulsive disorder. Effects of chronic clomipramine treatment Arch Gen Psychiatry (1988) 45.167-172.
31. Price LH, Malisson RT, McDougle CJ, McCance-Katz EF, Owen KR, Heninger GR. Neurobiology of tryptophan depletion in depression. Effects of m-chlorophenylpiperazine (mCPP). Neuropsychopharmacology (1997) 17.342-350.
32. Moreau J-L, Jenck F, Martin JR, Mortas P S, Haefely WE. Antidepressant treatment prevents chronic unpredictable . mild stress-induced anhedonia as assessed by ventral tegmentum self stimulation behavior in rats. Eut Neumpsychopharmacoltf 992) 2.43-49.
33. Moreau J-L, Jenck F, Martin JR, Pem'n S, Haefely WE. Effects of repeated mild stress and two antidepressant treatments on the behavioural response to 5-HT1C receptor activation in rats. Psychopharmacol (1993) 110.140-144.
34. Lesch KP, Hough CJ, Aulakh CS, Wolozin BL, Tolliver TJ, Hill Jl, Akiyoshi J, Chuang DM, Murphy DL. Rupxetine modulates Gprotein as, aq and a 12 subunit messenger RNA expression in rat brain. Eur J Phamacol Molec Pharm (1992) 227.233-237.
35. Berendsen HH. Interactions between 5-hydroxytryptamine receptor subtypes. is a disturbed receptor balance contributing to the symptomatology of depression in humans? Pharmacol Ther(IQ95) 66.17-37.
36. Maj J, Moryl E. Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm Gen Sec/(1992) 88.143-156.
37. Maj J, Moryl E. Effects of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists. Eur Neuropsychopharmacol ( 1993) 3.85-94.
38. Kennet! GA, Ughtowler S, de Biasi V, Stevens NC, Wood ND, Tulloch IF, Blackburn TP. Effect of chronic administration of selective 5-hydroxyfryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology (1994) 33.1581-1588.
39. Aulakh CS, Mazzola-Pomietto P, Murphy DL. Long-term antidepressant treatment restores clonidine's effect on growth hormone secretion in a genetic animal model of depression. PharmacolBiochemBehav(\996) 55.265-268.
40. Aulakh CS, Mazzola-Pomietto P, Murphy DL. Long-term antidepressant treatments alter 5-HT2A and 5-HT2C receptor-mediated hyperthermia in Fawn-Hooded rats. EurJ Pharmacol (1995) 282.65-70.
41. Aulakh CS, Wozniak KM, Hill JL, Devane CL, Tolliver TJ, Murphy DL Differential neuroendocrine responses to the 5-HT agonist m-chlorophenylpiperazine in fawn-Hooded rats relative to Wistar and Sprague-Dawley rats. Neuroendocrinology(19B8) 48.401-406.
42. Barker EL, Sanders-Bush E. 5-Hydroxytryptamine1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5dimethoxyphenyl)-2-aminopropane. Mot Pharmacol (1993) 44.725-730.
43. Laakso A, PaMmaki EP, Kuoppamaki M, Syvalahti E, Hietala J. Chronic citalopram and fluoxetine treatments upregulate 5- HT2C receptors in the rat choroid plexus. Neuropsychopharmacology(\996) 15.143-151.
44. Tohda M, Watanabe H. Imipramine-induced increase in 5HT2C receptor mRNA level in the rat brain. Neurosci Res (1996)24.189-193.
45. Mizuta T, Segawa T. Chronic effects of imipramine and lithium on 5-HT receptor subtypes in rat frontal cortex hippocampus and choroid plexus quantitative receptor autoradiographic analysis. Jpn J Pharmacol (1989) 50.315326.
46. Whileford HA, Jarvis MR, Stedman TJ, Pond S, Csemansky JG. Mianserin-induced up-regulation of serotonin receptors on normal human platelets in vivo. Life So (1993) 53.371-376.
47. Roth BL, Hamblin M, Ciaranello RD. Regulation of 5-HT2 and 5HT1C serotonin receptor levels. Methodology and mechanisms. Neuropsychophamnacol (1990) 3.427-433.
48. Borsini F, Cesana R, Mennini T. Evidence that imipramine activates 5-HT1C receptor function. Eur J Pharmacol (1991) 203.359-364.
49. Zhang X, Peng L, Chen Y, Hertz L. Stimulation of glycogenolysis in astrocytes by fluoxetine, an antidepressant acting like 5-HT. Neuroreport (1993) 4.12351238.
50. Jenck F, Moreau JL, Mutel V, Martin JR, Haefely WE. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol (1993)231.223-229.
51. Jenck F, Moreau JL, Mutel V, Martin JR. Brain 5-HT1C receptors and antidepressants. Prog Neuropsycho-pharmacol Biol Psychiatry (1994) 18.563-574.
52. Chen Y, Peng L, Zhang X, Stolzenburg JU, Hertz L. Further evidence that fluoxetine interacts with a 5-HT2C receptor in glial cells. Brain Res Bu//(1995) 38.153-159.
53. Akiyoshi J, Isogawa K, Yamada K, Nagayama H, Fujii I. Effects of antidepressants on intracellular Ca2+ mobilization in CHO cells transfected with the human 5-HT2C receptors. Biol Psychiatry (1996) 39.1000-1008.
54. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Koppamaki M, Syvalahti E, Hietala J. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor. Psychopharmacology(W96) 126.234-240.
55. Ni YG, Miledi R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Nail Acad SciUSA (1997) 94.20362040.
56. Lucki l, Kreider MS, Simansky KJ. Reduction of feeding behaviour by the serotonin uptake inhibitor sertraline. Psyc/K£to7T)aco/(1988) 96.289-295.
57. Broekkamp CLE, Berendsen HHG. The importance of 5-HT1C receptors for anti-depressant effects. Pol J Pharmacol Pharm (1992)44.suppl20.
58. Berendsen HHG, Broekkamp CLE. Comparison of stimulus properties of fluoxetine and 5-HT receptor agonists in conditioned taste aversion procedure. Eur J Pharmacol (1994) 253.83-89.
59. Leysen D, Kelder J. Ligands for the 5-HT2C receptor as potential antidepressants and anxiolytics. In Trends in Drug Research II. Proceedings of the 11th Noordwijkerhout-Camerino Symposium, van der Goot H (Ed), Elsevier, Amsterdam (1998)
60. Marek GJ, Li M, Seiden LS. Evidence for involvement of 5hydroxytryptamine-1 receptors in antidepressant-like drug effects on differential-reinforcement-of-low-rate 72-second behavior. J Pharmacol ExpJher (1989) 250.60-71.
61. Lucki I, Ward HR, Frazer A. Effect of 1-
62. Berendsen HH, Broekkamp CL. Attenuation of 5-HT1A and 5HT2 but not 5-HT1C receptor mediated behaviour in rats following chronic treatment with 5-HT receptor agonists, antagonists or anti-depressants. Psychopharmacol (1991) 105.219-224.
63. Leysen D, Linders JTM, Ottenheijm HCJ. 5-HT2 Antagonists. a concept for the treatment of schizophrenia. Curr Pharm Des (1997)3.367-390.
64. Sanchez C, Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacol (1997) 129.197-205.
65. Pomerantz SM, Hepner BC, Wertz JM. 5-HT1A and 5-HT1C/1D receptor agonists produce reciprocal effects on male sexual behavior of rhesus monkeys. Eur J Pharmacol (1993) 243.227234.
66. Hoyer D. Functional correlates of serotonin 5-HT1 recognition sites. J Receptor Res (1988) 8.59-81.
67. Schoeffter P, Hoyer D. Interaction of arylpiperazines with 5HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors. Do discriminatory 5-HT1B receptor ligands exist? NaunSchmiedeb Arch Pharmacol (1989) 339.675-683.
68. Bonhaus DW, Bach C, DeSouza A, Salazar FHR, Matsuoka BD, Zuppan P, Chan HW, Eglen RM. The pharmacology and distribution of human 5-hydroxytryptamine 2B (5-HT2B) receptor gene products. comparison with 5-HT2A and 5HT2C receptors. Br J Pharmacol (1995) 115.622-628.
69. Thomas DR, Gager TL, Holland V, Brown AM, Wood MD. mChlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor. Neuroreport (1996) 7.14571460.
70. Silverstone PH, Rue JE, Franklin M, Hallis K, Camplin G, Laver D, Cowen PJ. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. Int Clin Psychopharmacol (1994) 9.173-178.
71. Kahn RS, Kalus O, Wetzler S, Cahn W, Asnis GM, van Praag HM. Effects of serotonin antagonists on mchlorophenylpiperazine-mediated responses in normal subjects. Psychiatry Res (1990) 33.189-198.
72. Baumann MH, Rutter JJ, Auerbach SB. Intravenous administration of the serotonin agonist mchlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats. Neuropharmacol (1993) 32.1381 -1386.
73. Baumann MH, Mash DC, Staley JK. The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. Neuroreport (1995) 6.2150-2152.
74. Callahan PM, Cunningham KA. Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP). Eur .'
75. Rorella D, Rabin RA, Winter JC. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of mchlorophenylpiperazine. Psychopharmacol (1995) 119.222-230.
76. Gommans J, Hijzen TH, Maes RM, Olivier B. Discriminative stimulus properties of mCPP. Evidence for a 5-HT2C receptor mode of action. Psychophamacol (1998) 137.292302.
77. Kennett GA, Curzon G. Evidence that mCPP may have behavioral effects mediated by central 5-HT1C receptors. BrJPharmacol(î9B3) 94.137-147.
78. Li AA, Marek GJ, Hand TH, Seiden LS. Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite mchlorophenylpiperazine. Eur J Pharmacol (1990) 177.137144.
79. Asnis GM, Wetzler S, Sanderson WC, Kahn RS, van Praag HM. Functional interrelationship of serotonin and norepinephrine. Cortisol response to mCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects. Psychiatry Res (1992) 43.6576.
80. Lawlor BA, Sunderland T, Mellow AM, Hill JL, Molchan SE, Murphy DL. Hyperresponsivity to the serotonin agonist mchlorophenylpiperazine in Alzheimer's disease. A controlled study. Arch Gen Psychiatry (1989) 16.542-549.
81. Anand A, Chamey DS, Delgado PL, McDougle CJ, Heninger GR, Price LH. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry (1994) 151.1626-1630.
82. Maes M, Meltzer HY. Effects of metachlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers. Psychiatry Res (1996) 64.147-159.
83. Koreen AR, Lieberman JA, Alvir J, Chakos M. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls. Neuropsychophamaco! (1997) 16.61-68.
84. Klaassen T, Pian KLH, Westenberg HGM, Den Boer JA, van Praag HM. Serotonin syndrome after challenge with the 5HT agonist meta-chlorophenylpiperazine. Psychiatry Res (1998)79.207-212.
85. Bagdy G, Arato M. Gender-dependent dissociation between oxytocin but not ACTH, cortisol or TSH responses to m-chlorophenylpiperazine in healthy subjects. Psychopharmacol (W9S) 136.342-348.
86. Aloi JA, Insel TR, Mueller EA, Murphy DL. Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. Life Sci(1984) 34.13251331.
87. Chamey DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry (1988) 45.177-185.
88. Mellow AM, Lawler BA, Sunderland T, Mueller EA, Molchan SE, Murphy DL. Effects of daily m-chlorophenylpiperazine in eldery depressed patients. initial experience with a srotontn agonist. Biol Psychiatry (1990) 28.588-594.
89. Conn PJ, Sanders-Bush Ft. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT2 and 5-HT1C) receptors. J Pharmacol Exp Trter (1987) 242.552-557.
90. Lee HS, Bastani B, Friedman L, Ramirez L, Meltzer HY. Effect of serotonin agonist, MK-212, on body temperature in schizophrenia. Bol Psychiatry (1992) 31.460-470.
91. Hendrix JC, Ward JS. Shannon HE. Evidence that the discriminative stimulus effects of MK212 are mediated by 5HT1C receptors in rats. Fed Am Soc Exp Biol J (1992) 6.A1B69.
92. Chamey DS, Woods SW, Goodman WK, Heninger GR. Serotonin function in anxiety. II Effects of the serotonin . agonist m-CPP in panic disorder patients and healthy subjects. Psychopharmacol (1987) 92.14-24.
93. Kahn RS, Wetzler S, van Praag HM, Asnis GM, Strauman T. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res (1988) 25.101-104.
94. Bastani B, Nash JF, Meltzer HY. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessivecompulsive disorder. Arch Gen Psychiatry (1990) 47.833-839.
95. Hollander E, DeCaria C, Gully R, Nitescu A, Suckow RF, Gorman JM, Klein-DF, Uebowitz MR. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsesive-compulsive disorder. Psychiatry Res (1991 ) 36.1-17.
96. Barrett JE, Vanover KE. 5-HT receptors as targets for the development of novel anxiolytic drugs. models, mechansms and future directions. Psychopharmacol (1993) 112.1-12.
97. Pigott TA, Hill JL, Grady TA, Heureux F, Bernstein S, Rubenstein CS, Murphy DL. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to iv mCPP. Biol Psychiatry (1993) 33.3-14.
98. Germine M, Goddard AW, Sholomskas DE, Woods SW, Chamey DS, Heninger GR. Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects. influence of reduction in intravenous dosage. Psychiatry Res (1994) 54.115-133.
99. Sevy S, Brown SL, Wetzler S, Kotler M, Molcho A, Plutchik R, van Praag HM. Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. Psychiatry Res (1994) 53.219-229.
100. Goodman WK, McDougle CJ, Price LH, Barr LC, Hills OF, Caplik JF, Chamey DS, Heninger GR. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder. Absence of symptom exacerbation. Biol Psychiatry (1995) 38.138-149.
101. Kennedy AJ, Gibson EL, O Connell MT, Curzon G. Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responses to mCPP. Psychopharmacol (1993) 113.262-268.
102. Wetzler S, Asnis GM, DeLecuona JM, Kalus O. Serotonin function in panic disorder. Intravenous administration of meta-chlorophenylpiperazine. Psychiatry Res (1996) 64.77-82.
103. Murphy DL, Mueller EA, Hill JL, Tolliver TJ, Jacobsen FM. Comparative anxiogenic, neuroendocrine, and other physiological effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacol'(1989) 98.275-282.
104. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW. Anxiogenic 'effects of m-CPP in patients with panic disorder, comparison to caffeine's anxiogenic effects. Biol Psychiatry (1991) 30.973-984.
105. Gorman JM, LJebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, Davies SO, Klein DF. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychophamacol (1987) 7.329-332.
106. Boyer WF, McFadden GA, Feighner JP. The efficacy of selective serotonin re-uptake inhibitors in anxiety and obsessive-compulsive disorder. In. Selective serotonin reuptake inhibitors, Perspectives in Psychiatry Vol 1. Feighner JP, Boyer WF (Eds) (1991).109-117.
107. Boyer WF, Feighner JP. An overview of paroxetine. J Clin Psychiatry (1992) 53 (suppl 2).3-6.
108. Griebel G, Moreau J-L, Jenck F, Misslin R, Martin JR. Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacol (1994) 113.463-470.
109. Zuardi AW. 5-HT-related drugs and human experimental anxiety. Neurosci Biobehav Rev (1990) 14.507-510.
110. Kahn RS, Siever LJ, Gabriel S, Amin F, Stem RG, DuMont K, Apter S, Davidson M. Serotonin function in schizophrenia. Effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects. Psychiatry Res (1992) 43.1 -12.
111. Cowen PJ, Sargent PA, Williams C, Goodall EM, Orlikov AB. Hypophagic, endocrine and subjective responses to mchlorophenylpiperazine in healthy men and women. Hum Psychopharmacol (1995) 10.385-391.
112. Walsh AE, Smith KA, Oidman AD, Williams C, Goodall EM, Cowen PJ. m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacol(1994) 116.120-122.
113. Sargent PA, Sharpley AL, Williams C, Goodall EM, Cowen PJ. 5HT(2C) receptor activation decreases appetite and body weight in obese subjects. Psychopharmacol (1997) 133.309312.
114. Levitan RD, Kaplan AS, Joffe RT, Levitt AJ, Brown GM. Hormonal and subjective responses to intravenous metachlorophenylpiperazine in bulimia nervosa. Arch Gen Psychiat (1997) 54.521-527.
115. Cowen PJ, Clifford EM, Walsh AE, Williams C, Fairbum CG. Moderate dieting causes 5-HT2C receptor supersensitivity. Psycho/ Med (1996) 26.1155-1159.
116. Curzon G, Gibson EL, Oluyomi AO. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci(1997) 18.21-25.
117. O'Hanlon K. Obesity and non-insulin dependent diabetes mellitus, 22-23 April 1998, The Royal Society, London, UK. Dnjgs(1998)1.191-193.
118. Krystal JH, Webb E, Cooney N, Kranzler HR, Chamey DS. Specificity of ethanollike effects elided by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry (1994) 51.898-911.
119. Hommer D, Andreasen P, Rio D, Williams W, Ruttimann U, Momenan R, Zametkin A, Rawlings R, Unnoila M. Effects of mchlorophenylpiperazine on regional brain glucose utilization. A positron emission tomographic comparison of alcohol! and control subjects. J Neurosci (1997) 17.1789-2806.
120. Pandey SC, Lumeng L, Li TK. Serotonin2C receptors and serotonin2C receptor-mediated phosphoinositide hydrolysis in the brain of alcohol-preferring and alcohol-nonpreferring rats. Alcohol Clin Exp Res (1996) 20.1038-1042.
121. Lee MA, Meltzer HY. Blunted oral body temperature response to MK-212 in cocaine addicts. Drug Alcohol Depend (1994) 35.217-222.
122. Kalkman HO. Hypersensitivity to metachlorophenylpiperazine (mCPP) in migraine and drug withdrawal. Int J Clin Pharmacol Res (1997) 17.75-77.
123. Leone M, Attanasio A, Croci D, Ferraris A, D Amico D, Grazzi L, Nespolo A, Bussone G. 5-HT(1A) receptor hypersensitivity in migraine is suggested by the m-chlorophenylpiperazine test Neuroreport (1998) 9.2605-2608.
124. Panconesi A, Sicuteri R. Headache induced by serotonergic agonists - a key to the interpretation of migraine pathogenesis? Cephalalgia (1997) 17.3-14.
125. Silberstein SD. Serotonin (5-HT) and migraine. Headache (1994)34.408-417.
126. Carver JG, Grahame-Smith DG, Johnson ES, Madgwick Z. The effects of 5-HT and m-chlorophenylpiperazine (m-CPP) on the efflux of (3H)-5-HT from human perfused platelets. Br J Clin Pharmacol (1993) 35.473-478.
127. Brewerton TD, Murphy DL, Mueller EA, Jimerson DC. Induction of migrainelike headaches by the serotonin agonist mchlorophenylpiperazine. Clin Pharmacol Ther (1988) 43.605609.
128. Gordon ML, LJpton RB, Brown SL, Nakraseive C, Russell M, ' Pollack SZ, Kom ML, Merriam A, Solomon S, van Praag HM. . Headache and cortisol responses to mchlorophenylpiperazine are highly correlated. Cephalagia (1993)13.400-405.
129. Constantin M, Pognat JF. Comparative study of oxaflozane '. urinary metabolism in man , the dog and the rat Identification of the principal metabolites. Arzneim Forsch (1979)29.109-114..
130. Hache J, Duchene-Marullaz P, Streichenberger G. Pharmacologie properties of a new nontricyclic antidepressant. oxaflozane (1766 Cerm). Therapie (1974) ; 29.81-93.
131. Bertolino A, palermo M, Porro V. Oxaflozane, a new non tricyclic antidepressant in the treatment of anxietyi depressions syndromes. Acta 77ier(1985) 11.209-218.
132. Rascol A, Maurel H, David J, Layani M. Preliminary clinical results of a new non tricyclic antidepressive drug. oxaflozane. Therapie (1974) 29.95-99.
133. Aguglia E. On the therapetic value of axaflozane. Its application in the treatment of emotional disturbances of the anxious-depressive type accompanied by somatic manifestations. Acta 77jer(1986) 12.259-267.
134. Rascol A, Maurel H, David J, Layani M. Preliminary results of i clinical trials of oxaflozane, a new nontricyclic antidepressant Therapie (1974) 19.95-99.
135. Price GW. 3rd IUPHAR satellite meeting on serotonin, July 30 - August 3 1994, Chicago, USA. serotonin '94. Expert Opin Invest Dnjgs (1995) 4.45-47.
136. Leysen D. Chirality in drug design. In Proceedings of the XlVth International Symposium on medicinal chemistry. Awouters F (Ed), Elsevier, Amsterdam (1997) 28.257-269.
137. Sanders-Bush E, Breeding M. Choroid plexus epithelial cells in primary culture. a model of 5HT1C receptor activation by hallucinogenic drugs. Psychopharmacol (1951) 105.340-346.
138. Bum's KD, Breeding M, Sanders-Bush E. Dextro LSD not its nonhallucinogenic congeners is a potent serotonin 5HT-1C receptor agonist J Pharmacol Exp Ther(1991) 258.891-896.
139. Glennon RA, Teitler M, Sanders-Bush E. Hallucinogens and serotonergic mechanisms. NIDA Res Mongr(1992) 119P.131135.
140. Egan CT, Herrick DK, Miller K, Glennon RA, Teitler M. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacol (199B) 136.409-414.
141. Moreau J-L, Bös M, Jenck F, Martin JR, Mortas P, Wichmann J. 5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur Neuropsychopharmacol (1996) 6.169-175.
142. Bös M, Jenck F, Martin JR, Moreau J-L, Sleight AJ, Wichmann J, Widmer U. Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-5indol-1-yl)-1methylethylamines and 2-{indeno[1,2-u)pyrrol-1-yl}-1methylethylamines. Improved therapeutics for obsessive compulsive disorder. J Med Chem (1997) 40.2762-2769.
143. Martin JR, Bös M, Jenck F, Moreau J-L, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HHG, Broekkamp CLE, Ruigt GSF, Köhler C, van Delft AML. 5-HT2C receptor agonists. pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther (1998) 286.913-924.
144. Bös M, Jenck F, Martin JR, Moreau JL, Mutel V, Sleight AJ, Widmer U. Synthesis, pharmacology and therapeutic '[ potential of 10-methoxypyrazino[1,2-a]indoles, partial I agonists at the 5-HT2C receptor. Eur J Med Chem (1997) ! 32.253-261.
145. Albertini S, Bös M, Gocke E, Kirchner S, Muster W, Wichmann J. 'i Suppression of mutagenic activity of a series of 5-HT2C receptor agonists by the incorporation of a gem-dimethyl group. SAR using the Ames test and a DNA. unwinding assay. Mutagenesis (1998) 13.397-403.
146. AKZO NV (Cartier P, Monteil A, Poisson C). Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl}-2pyridinyl] piperazines. EP-00370560-B (1989).
147. AKZO NOBEL NV (Broekkamp CLE). Treatment of urinary incontinence. WO-09833504 (1998).
148. AKZO NOBEL NV (Broekkamp CLE, Wieringa JH, Leysen D). Derivatives of azetidine and pyrrolidine. EP-00863136-A (1997).